In this issue:
Biologic adherence and persistence in patients with psoriasis
Mammography prior to initiation of biologic agents
Adverse events with dupilumab in atopic dermatitis and related conditions
Risankizumab in improvement of response to plaque psoriasis
Biologic therapies for plaque psoriasis with concomitant viral hepatitis
Time to loss of response following withdrawal of ixekizumab
Blood screening before initiation of biologics
Long-term biologic persistence for psoriasis and psoriatic arthritis
Number needed to treat for biologic drugs in moderate-to-severe psoriasis
Direct comparison of real-world effectiveness of biologics in psoriasis
Please login below to download this issue (PDF)